http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 26 May 2026 16:44:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PepGen+Inc.+++++++++++++++For%3A+May+21++Filed+by%3A+Kasraian+Kasra/26550769.html si-local-file:///var/storage/secattach/20260526/26550769.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PepGen+Inc.+++++++++++++++For%3A+May+21++Filed+by%3A+Kasraian+Kasra/26550769.html Tue, 26 May 2026 16:44:00 -0400 O.50075559 PEPG http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PepGen+Inc.+++++++++++++++For%3A+May+21++Filed+by%3A+Kasraian+Kasra/26550769.html si-local-file:///var/storage/secattach/20260526/26550769.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PepGen+Inc.+++++++++++++++For%3A+May+21++Filed+by%3A+Kasraian+Kasra/26550769.html Tue, 26 May 2026 16:44:00 -0400 O.50075559 PEPG http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++PepGen+Inc.++++++++++++++++++++++++++/26538158.html si-local-file:///var/storage/secattach/20260522/26538158.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++PepGen+Inc.++++++++++++++++++++++++++/26538158.html Fri, 22 May 2026 06:03:00 -0400 O.50075559 PEPG http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++PepGen+Inc.++++++++++++++++++++++++++/26538158.html si-local-file:///var/storage/secattach/20260522/26538158.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++PepGen+Inc.++++++++++++++++++++++++++/26538158.html Fri, 22 May 2026 06:03:00 -0400 O.50075559 PEPG http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PepGen+Inc.+++++++++++++++For%3A+May+21/26531489.html si-local-file:///var/storage/secattach/20260521/26531489.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PepGen+Inc.+++++++++++++++For%3A+May+21/26531489.html Thu, 21 May 2026 07:30:00 -0400 O.50075559 PEPG http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PepGen+Inc.+++++++++++++++For%3A+May+21/26531489.html si-local-file:///var/storage/secattach/20260521/26531489.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PepGen+Inc.+++++++++++++++For%3A+May+21/26531489.html Thu, 21 May 2026 07:30:00 -0400 O.50075559 PEPG http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Press+Releases/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pepgen.com%2F&amp;esheet=54539630&amp;newsitemid=20260521566873&amp;lan=en-US&amp;anchor=PepGen+Inc.&amp;index=1&amp;md5=626cbc9444f4377aa43c1814ad00b917" shape="rect">PepGen Inc.</a> (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-breaking oral presentation will include analyses of individual patient mis-splicing data from the PGN-EDODM1 program, as well as natural history data characterizing mis-splicing in patients with myotonic http://www.streetinsider.com/Business+Wire/PepGen+Announces+Presentations+at+the+15th+International+Myotonic+Dystrophy+Consortium+Highlighting+Clinical+Data+from+the+PGN-EDODM1+Program/26531269.html Thu, 21 May 2026 07:00:00 -0400 A.05477717 A.06822034 A.31066700 A.50216399 O.20026344 O.20094008 O.22422661 O.22795517 O.50075559 PEPG